Carregant...
Personalization of Chemotherapy for Metastatic Pancreatic Cancer
Erlotinib is an approved drug for the treatment of advanced pancreatic cancer; however, its survival benefit is small and its cost is high, and the decision to use the drug may often be personalized according to the patient’s background. A 72-year-old Asian man in good general condition chose gemcit...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Libertas Academica
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4116360/ https://ncbi.nlm.nih.gov/pubmed/25093005 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CCRep.S14478 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|